Abstract
Supramolecular medicinal chemistry field has been a quite rapidly developing, increasingly active and newly rising interdiscipline which is the new expansion of supramolecular chemistry in pharmaceutical sciences, and is gradually becoming a relatively independent scientific area. Supramolecular drugs could be defined as medicinal supermolecules formed by two or more molecules through non-covalent bonds. So far a lot of supermolecules as chemical drugs have been widely used in clinics. Supermolecules as chemical drugs, i.e. supramolecular chemical drugs or supramolecular drugs, which might have the excellences of lower cost, shorter period, higher potential as clinical drugs for their successful research and development, may possess higher bioavailability, better biocompatibility and drug-targeting, fewer multidrug-resistances, lower toxicity, less adverse effect, and better curative effects as well as safety, and therefore exhibit wide potential application. These overwhelming advantages have drawn enormous special attention. This paper gives the definition of supramolecular drugs, proposes the concept of supramolecular chemical drugs, and systematically reviews the recent advances in the research and development of supermolecules, including organic and inorganic complex ones as chemical drugs in the area of antitumor, anti-inflammatory, analgesic, antimalarial, antibacterial, antifungal, antivirus, anti-epileptic, cardiovascular agents and magnetic resonance imaging agents and so on. The perspectives of the foreseeable future and potential application of supramolecules as chemical drugs are also presented.
Article PDF
Similar content being viewed by others
References
Lehn J M. Supramolecular Chemistry-Concepts and Perspectives. Weinheim: VCH, 1995; Translated by Shen X H. Supramolecular Chemistry-Concepts and Perspectives (in Chinese). Beijing: Peking University Press, 2002
Lehn J M, Atwood J L, Davies L E D, MacNIcol D D, Vögtle F. Comprehensive Supramolecular Chemistry. Vol. 1–11. New York: Pergamon, 1996
Liu Y, You C C, Zhang H Y. Supramolecular Chemistry-Molecular Recognition and Assembly of Synthesized Receptors (in Chinese). Tianjin: Nankai University Press, 2001
Steed J W, Atwood J L. Supramolecular Chemistry. Chichester: John Wiley & Sons, 2000; Translated by Zhao Y P, Sun Z. Supramolecular Chemisty (in Chinese). Beijing: Chemical Industry Press, 2006
Dodziuk H. Introduction to Supramolecular Chemistry. Dordrecht: Kluwer Academic Publishers, 2002
Translated by Zhang X, Lin Z H, Gao Q Vögtle F ed). Supramolecular Chemisty (in Chinese). Jilin: Jilin University Press, 1995
Tong L H, Shen B J. Physical Methods in Supramolecular Chemistry (in Chinese). Beijing: Science Press, 2004
Sun X Q, Meng Q, Yan H B. Introduction of Supramolecular Chemisty (in Chinese). Beijing: China Petrochemical Press, 2000
Bianchi A, Bowman-James K, Garcia-Espana E. Supramolecular Chemistry of Anions. New York: John Wiley & Sons, 1997
Yui N. Supramolecular Design for Biological Applications. Boca Raton: CRC Press, 2002
Jones W, Rao C N R. Supramolecular Organization and Materials Design. Cambridge: Cambridge University Press, 2002
Schneider H J, Yatsimirsky A K. Principles and Methods in Supramolecular Chemistry. Chichester: John Wiley & Sons, 2000
Shen J C, Sun J Q. Research development of supramolacular science. Bull Chin Aca Sci (in Chinese), 2004, 19(6): 420–424
Bertini I, Sigel A, Sigel H. Handbook of Metalloproteins. New York: Marcel Dekker, 2001
Li W. Biological Supramolecular Systems (in Chinese). Beijing: Chemical Industry Press, 2003
Penadés S. Host-Guest Chemistry-Mimetic Approaches to Study Carbohydrate Recognition. Berlin: Springer, 2002
Cho S K. Synthetic Multivalent Molecules-Concepts and Biomedical Applications. New Jersey: John Wiley & Sons, 2004
Wu C T. Crown Ether Chemistry (in Chinese). Beijing: Science Press, 1992
Gloe K. Macrocyclic Chemistry-Current Trends and Future Perspectives. Berlin: Springer, 2005
Simons C. Nucleoside Mimetics-Their Chemistry and Biological Properties. Australia: Gordon and Breach Science Publishers, 2001
Yang M. Molecular Recognition in the Drug Research (in Chinese). Beijing: Beijing Medical University-Peking Union Medical College Union Press, 1999
Li R X, Yang J J. Molecular Bionics and Their Application (in Chinese). Beijing: Chemical Industry Press, 2003
Yan J M, Zhou C H, Xie R G. Advance in the artificial receptors and enzymes of cyclophane. Chin J Org Chem (in Chinese), 1995, 15(6): 577–586
Luo M M, Guo J S, Zhou C H, Xie R G. Design and synthesis of imidazolium cyclophane. Heterocycles, 1995, 41(7): 1421–1424
Zhou C H, Xie R G, Zhao H M. Convenient and efficient synthesis of imidazolium cyclophanes. Org Prep Proc Int, 1996, 28(3): 345–347
Liu Z C, Zhou C H, Su X Y, Xie R G. First synthesis of estrogen-imidazolium cyclophanes. Synth Commun, 1999, 29(17): 2979–2983
Jiang H Y, Zhou C H, Luo K, Chen H, Lan J B, Xie R G. Chiral imidazole metalloenzyme models: Synthesis and enantioselective hydrolysis for α-amino acid esters. J Mol Catal A: Chem, 2006, 260(1-2): 288–294
Wei X, Liu J, Zhang G L, Jiang Z L, Zhou C H, Luo K, Xie R G. An effective methodology to novel larger imidazolium cyclophanes. Lett Org Chem, 2005, 2: 507–511
Gao G, Xiao R, Yuan Y, Zhou C H, Xie R G. Efficient imidazolium catalysts forbenzoin condensation. J Chem Res, 2002, 6: 262–263
Wu J, Mi J L, Zhou C H. Advance in histamine H3 receptor ligands. Chin Pharm J (in Chinese), 2007, 46(6): 404–409
Song C Z, Zhou C H, Yuan Y. Advance in sulfonamides as carbonic anhydrase inhibitors. Chin J New Drugs (in Chinese), 2007, 16(18): 1438–1444
Meng J P, Lu Y H, Yibulayin H, Zhou C H. Advances in the research of benzimidazole compounds as enzyme inhibitors. Chin J Biochem Pharm (in Chinese), 2008, 29 (6): 422–425
Yu K G, Zhou C H, Li D H. Advances in the macrocyclic drugs. Chin Pharm J (in Chinese), 2008, 43(7): 481–488
Clarke M J, Zhu F C, Frasca D R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev, 1999, 99(9): 2511–2533
Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm Chem Life Sci, 2007, 340(3): 117–126
Dai G F, Wang M W. Progress in pharmaceutical applications of cyclodextrin and its derivatives. Chin J New Drugs (in Chinese), 2005, 14(11): 1261–1264
Deng S M. Study on the drug-Cyclodextrin supramolecular system. Dissertation for the Doctoral Degree (in Chinese). Guangzhou: South China University of Technology, 1998
Beni S, Szakacs Z, Cserniak O, Barcza L, Noszal B. Cyclodextrin/imatinib complexation: Binding mode and charge dependent stabilities. Eur J Pharm Sci, 2007, 30(2): 167–174
Horvath G, Premkumar T, Boztas A, Lee E, Jon S, Geckeler K E. Supramolecular nanoencapsulation as a tool: Solubilization of the anticancer drug trans-dichloro(dipyridine)platinum(II) by complexation with β-cyclodextrin. Mol Pharm, 2008, 5(2): 358–363
Melo P S, Justo G Z, Azevedo M B M, Duran N, Haun M. Violacein and its β-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Toxicology, 2003, 186(3): 217–225
Wang F J, Blanco E, Ai H, Boothman D A, Gao J M. Modulating β-lapachone release from polymer millirods through cyclodextrin complexation. J Pharm Sci, 2006, 95(10): 2309–2319
Menuel S, Joly J P, Courcot B, Elysee J, Ghermani N E, Marsura A. Synthesis and inclusion ability of a bis-β-cyclodextrin pseudocryptand towards busulfan anticancer agent. Tetrahedron, 2007, 63(7): 1706–1714
Liu Y, Chen G S, Chen Y, Cao D X, Ge Z Q, Yuan Y J. Inclusion comp lexes of paclitaxel and oligo (ethylenediamino) bridged bis(β-cyclodextrin)s: Solubilization and antitumor activity. Bioorg Med Chem, 2004, 12(22): 5767–5775
Jong M R, Knegtel R M A, Grootenhuis P D J, Huskens J, Reinhoudt D N. A method to identify and screen libraries of guests that complex to a synthetic host. Angew Chem Int Ed, 2002, 41(6): 1004–1008
Krause-Heuer A M, Wheate N J, Tilby M J, Pearson D G, Ottley C J, Aldrich-Wright J R. Substituted β-cyclodextrin and calix[4]arene as encapsulatory vehicles for platinum(II)-based DNA intercalators. Inorg Chem, 2008, 47(15): 6880–6888
Comuzzi C, Cogoi S, Overhand M, Marel G A V, Overkleeft H S, Xodo L E. Synthesis and biological evaluation of new pentaphyrin macrocycles for photodynamic therapy. J Med Chem, 2006, 49(1): 196–204
Desroches M C, Bautista-Sanchez A, Lamotte C, Labeque B, Auchère D, Farinotti R, Maillard P, Grierson D S, Prognon P, Kasselouri A. Pharmacokinetics of a tri-glucoconjugated 5,10,15-(meta)-trihydroxyphenyl-20-phenyl porphyrin photosensitizer for PDT. A single dose study in the rat. J Photochem Photobiol B: Biol, 2006, 85(1): 56–64
Yu K G, Zhou C H, Li D H. Recent progress of porphyrin-based anticancer drugs. Chem Res Appl (in Chinese), 2007, 19(12): 1296–1303
Nyman E S, Hynninen P H. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol B: Biol, 2004, 73(1–2): 1–28
Ma J S. Development of second generational porphyrin-based photosensitizers. Photogra Sci Photochem (in Chinese), 2002, 20(2): 131–148
Hirakaa K, Kanehisaa M, Tamaia M, Asayamaa S, Nagaokaa S, Oyaizuc K, Yuasab M, Kawakami H. Preparation of pH-sensitive liposomes retaining SOD mimic and their anticancer effect. Colloids Surf B: Biointerfaces, 2008, 67(1): 54–58
Asayama S, Kasugai N, Kubota S, Nagaoka S, Kawakami H. Superoxide dismutase as a target enzyme for Fe-porphyrin-induced cell death. J Inorg Biochem, 2007, 101(2): 261–266
Wang Y, He Q Y, Che C M, Tsao S W, Sun R W Y, Chiu J F. Modulation of gold(II) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways. Biochem Pharm, 2008, 75(6): 1282–1291
Wang Y, He Q Y, Raymond Sun W Y, Che C M, Chiu J F. Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead. Eur J Pharmacol, 2007, 554(2-3): 113–122
Li DH, Diao J L, Yu K G, Zhou C H. Synthesis and anticancer activities of porphyrin induced anticancer drugs. Chin Chem Lett, 2007, 18(11): 1331–1334
Zhuang Y Y, Zhou C H, Wang Y F, Li D H. Advances of nitrogen mustard compounds in antitumor agents. Chin Pharm J (in Chinese), 2008, 44(17): 1281–1287
Cai J L, Li S, Zhou C H, Gan L L. Advances in imidazoles as anti-tumor agents. Chin J New Drugs (in Chinese), 2009, 18(7): in press
Yu K G, Liu J C, Zhou C H, Diao J L, Xu T, Li D H. Study on synthesis of porphyrin-nitroimidazole derivatives and their radiosensitization. Chin J Med Chem (in Chinese), 2008, 18(6): 414–419
Meng J P, Geng R X, Zhou C H, Gan L L. Advances in the research of benzimidazole compounds. Chin J New Drugs (in Chinese), 2009, 18(8): in press
Mi J L, Wu J, Zhou C H. Advances in the triazoles as anticancer drugs. West China J Pharm Sci (in Chinese), 2008, 23(1): 84–86
Bai X, Zhou C H, Mi J L. Research and application of triazoles. Chem Res Appl (in Chinese), 2007, 19(7): 721–729
Zhou C H, Hassner A. Synthesis and anticancer activity of novel chiral glucose derived bis-imidazoles and their analogs. Carbohydrates Res, 2001, 333(4): 313–326
Huang J, Zhou C H. Progress in nitroimidazoles as medicinal agents. Chin Clin J Traditional Chin West Med (in Chinese), 2007, 7(7): 538–542
Jamieson E R, Lippard S J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev, 1999, 99(9): 2467–2498
Qu P, He H, Liu X H. Antitumor activity and mechanism of rhodium complexes. Prog Chem (in Chinese), 2006, 18(12): 1646–1651
Liu W P, Zhang Y L, Sun R L. Future development of platinum anticancer drugs. Precious Met (in Chinese), 2005, 26(1): 47–52
Bagrova S G. Results of phaseIIclinical trials of cycloplatam in refractory solid tumors. Vopr Onkol, 2001, 47(6): 752–756
Raynaud F I, Boxall F E, Goddard P M, Valenti M, Jones M, Murrer B A, Abrams M, Kelland L R. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res, 1997, 3(11): 2063–2074
Brabec V, Kašpárková J, Vrána O, Nováková O, Cox J W, Qu Y, Farrell N. DNA modification by a novel bifunctional trinuclear platinum antitumor agent. Biochem, 1999, 38(21): 6781–6790
Ulrich S, Milod S. DE Patent, 19 824 653, 1999-08-26
Bjelosevic H, Spégel C, Snygg Å S, Gorton L, Elmrothc S K C, Perssona T. Synthesis and structural characterisation of novel platinum-based drug candidates with extended functionality by incorporation of bis(diphenylphosphino)ferrocene units as metal chelators. Tetrahedron, 2006, 62(18): 4519–4527
Gupta A, Mandal S K, Leblanc V, Descoeaux C, Asselin É, Bérubé G. Synthesis and cytotoxic activity of benzopyran-based platinum(II) complexes. Bioorg Med Chem Lett, 2008, 18(14): 3982–3987
Descôteaux C, Provencher-Mandeville J, Mathieu I, Perron V, Mandal S K, Asselin É, Bérubé G. Synthesis of 17β-estradiol platinum(II) complexes: biological evaluation on breast cancer cell lines. Bioorg Med Chem Lett, 2003, 13(22): 3927–3931
Gagnon V, St-Germain M È, Descôteaux C, Provencher-Mandeville J, Parent S, Mandal S K, Asselin E, Bérubé G. Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-Molecular modeling studies. Bioorg Med Chem Lett, 2004, 14(23): 5919–5924
Perron V, Rabouin D, Asselin É, Parent S, Gaudreault R C, Bérubé G. Synthesis of 17β-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and-independent breast tumor cells. Bioorg Chem, 2005, 33(1): 1–15
Berube G. US Patent, 7 153 844, 2004-01-08
N’soukpoé-Kossi C N, Descoeaux C, Asselin E, Tajmir-Riahi H A, Bérubé G. DNA Interaction with novel antitumor estradiol-platinum (II) hybrid molecule: A comparative study with cisplatin drug. DNA Cell Biol, 2008, 27(2): 101–107
Hall M D, Mellor H R, Callaghan R, Hambley T W. Basis for design and development of platinum(IV) anticancer complexes. J Med Chem, 2007, 50(15): 3403–3411
Kašpárková J, Nováková O, Vrána O, Intini F, Natile G, Brabec V. Molecular aspects of antitumor effects of a new platinum(IV) drug. Mol Pharmacol, 2006, 70(50): 1708–1719
Bednarski P J, Grünert R, Zielzki M, Wellner A, Mackay F S, Sadler P J. Light-activated destruction of cancer cell nuclei by platinum diazide complexes. Chem Biol, 2006, 13(1): 61–67
Mackay F S, Woods J A, Moseley H, Ferguson J, Dawson A, Parsons S, Sadler P J. A photoactivated trans-diammine platinum complex as cytotoxic as cisplatin. Chemistry, 2006, 12(11): 3155–3161
Chen Q, Huang Z, Chen H, Shapiro H, Beckers J, Hetzel F W. Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol, 2002, 76(2): 197–203
Kwon Y E, Whang K J, Park Y J, Kim K H. Synthesis, characterization and antitumor activity of novel octahedral Pt(IV) complexes. Bioorg Med Chem, 2003, 11(8): 1669–1676
Zhang C X, Lippard S J. New metal complexes as potential therapeutics. Curr Opin Chem Biol, 2003, 7(4): 481–489
Enzo A, Angela B, Elisabetta I. International conference on DNA conformation, modification and recognition in biomedcine. Brno Czech Republic, 2000, 1: 72–73
Chai X H, Wang F L, Huang J, Zhang J. Progress in investigation of metallodrugs. Chem Agen (in Chinese), 2008, 30(2): 99–104
Clarke M J. Ruthenium metallopharmaceuticals. Coord Chem Rev, 2003, 236(1–2): 209–233
Vargiu A V, Robertazzi A, Magistrato A, Ruggerone P, Carloni P. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations. J Phys Chem B, 2008, 112(14): 4401–4409
Sanna B, Debidda M, Pintus G, Tadolini B, Posadino A M, Bennardini F, Sava G, Ventura C. The anti-metastatic agent imidazolium transimidazoledimethylsulfoxidetetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activiated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys, 2002, 403(2): 209–218
Gopal Y N V, Konuru N, Kondapi A K. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl2(C6H6)-(dmso)]. Arch Biochem Biophys, 2002, 401(1): 53–62
Cebrián-Losantos B, Reisner E, Kowol C R, Roller A, Shova S, Arion V B, Keppler B K. Synthesis and reactivity of the aquation product of the antitumor complex trans-[RuIIICl4(indazole)2]−. Inorg Chem, 2008, 47(14): 6513–6523
Korfel A, Scheulen M E, Schmoll H J, Gründel O, Harstrick A, Knoche M, Fels L M, Skorzec M, Bach F, Baumgart J, Safi G, Seeber S, Thiel E, Berdel W E. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin Cancer Res, 1998, 4(11): 2701–2708
Lum B L, Srivanas S, Beck J T, Vesole D, Largey M, Valone F H, Sayre P H. Phase I trial of oral gallium maltolate in refractory malignancies. Proc. Am Soc Clin Oncol, 2003, 22: 943
Foteeva L S, Stolyarova N V, Timerbaev A R, Keppler B K. Capillary electrophoretic assay for the stability of tris(8-quinolinolato) gallium(III) in tablet formulations. J Pharm Biomed Anal, 2008, 48(1): 218–222
Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, Micksche M, Keppler B, Berger W. Resistance against novel anticancer metal compounds: Difference and similarities. Drug Resistance Updates, 2008, 11(1-2): 1–16
Rieter W J, Pott K M, Taylor K M L, Lin W. Nanoscale coordination polymers for platinum-based anticancer drug delivery. J Am Chem Soc, 2008, 130(35): 11584–11585
Moses M A, Brem H, Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell, 2003, 4(5): 337–341
Vail D M, Amantea M A, Colbern G T, Martin F J, Hilger R A, Working P K. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol, 2004, 31(13): 16–35
Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Delivery Rev, 2003, 55(3): 329–347
Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer, 2005, 5(3): 161–171
Fonseca C, Simões S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: Preparation, phsiochemical characterization and in vitro antitumoral activity. J Controlled Release, 2002, 83(2): 273–286
Brannon-Peppas L, Blanchette J O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev, 2004, 56(11): 1649–1659
Yoo H S, Park T G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Controlled Release, 2000, 68(3): 419–431
Mitra S, Gaur U, Ghosh P C, Maitra A N. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Controlled Release, 2001, 74(1-3): 317–323
Savic R, Luo L, Eisenberg A, Maysinger D. Micell nanocontainers distribute to defined cytoplasmic organelles. Science, 2003, 300(5619): 615–618
Hu Y Q, Kim M S, Kim B S, Lee D S. Synthesis and pH-dependent micellization of 2-(dIIsopropylamino)ethyl methacrylate based amphiphilic diblock copolymers via RAFT polymerization. Polymer, 2007, 48(12): 3437–3443
Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res, 2007, 24(6): 1029–1046
Yang X Q, Chen Y H, Yuan R X, Chen G H, Blanco E, Gao J M, Shuai X T. Folate-encoded and Fe3O4-loaded polymeric micelles for dual targeting of cancer cells. Polymer, 2008, 49(16): 3477–3485
Xu P S, Kirk E A V, Murdoch W J, Zhan Y H, Isaak D D, Radosz M, Shen Y Q. Anticancer efficacies of cisplatin releasing pH-responsive nanoparticles. Biomacromolecules, 2006, 7(3): 829–835
Feazell R P, Nakayama-Ratchford N, Dai H J, Lippard S J. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc, 2007, 129(27): 8438–8439
Shi G Y. Progress in the study of non-steroidal anti-imflammatory drugs. Chin J New Drugs (in Chinese), 1999, 8(9): 699–601
Weder J E, Dillon C T, Hambley T W, Kennedy B J, Lay P A, Biffin J R, Regtop H L, Davies N M. Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. Coord Chem Rev, 2002, 232(1–2): 95–126
Moya-Hernández M R, Mederos A, Domínguez S, Orlandinid A, Ghilardi C A, Cecconi F, González-Vergara E, Rojas-Hernández A. Speciation study of the anti-inflammatory drug tenoxicam (Htenox) with Cu(II): X-ray crystal structure of [Cu(tenox)2(py)2]·EtOH. J Inorg Biochem, 2003, 95(2–3): 131–140
Morgan Y R, Turner P, Kennedy B J, Hambley T W, Lay P A, Biffin J R, Regtop H L, Warwick B. Preparation and characterization of dinuclear copper-indomethacin anti-inflammatory drugs. Inorg Chim Acta, 2001, 324(1-2): 150–161
Trinchero A, Bonora S, Tinti A, Fini G, Spectroscopic behavior of copper complexes of nonsteroidal anti-inflammatory drugs. Biopolymers, 2004, 74(1-2): 120–124
Weder J E, Hambley T W, Kennedy B J, Lay P A, MacLachlan D, Bramley R, Delfs C D, Murray K S, Moubaraki B, Warwick B, Biffin J R, Regtop H L. Anti-inflammatory dinuclear copper(II) complexes with indomethacin. Synthesis, magnetism and EPR spectroscopy. crystal structure of the N,N-dimethylformamide adduct. Inorg Chem, 1999, 38(8): 1736–1744
Chaviara A T, Christidis P C, Papageorgiou A, Chrysogelou E, Hadjipavlou-Litina D J, Bolos C A. In vivo anticancer, anti-inflammatory, and toxicity studies of mixed-ligand Cu(II) complexes of dien and its Schiff dibases with heterocyclic aldehydes and 2-amino-2-thiazoline. crystal structure of [Cu(dien)(Br)(2a-2tzn)] (Br)(H2O). J Inorg Biochem, 2005, 99(11): 2102–2109
Zvimba J N, Jackson G E. Copper chelating anti-inflammatory agents; N 1-(2-aminoethyl)-N 2-(pyridin-2-ylmethyl)-ethane-1,2-diamine and N-(2-(2-aminoethylamino)ethyl)picolinamide: An in vitro and in vivo study. J Inorg Biochem, 2007, 101(1): 148–158
Zhou Q D, Hambley T W, Kennedy B J, Lay P A, Turner P, Warwick B, Biffin J R, Regtop H L. Syntheses and characterization of antiinflammatory dinuclear and mononuclear zinc indomethacin complexes. crystal structures of [Zn2(Indomethacin)4(L)2] (L = N,N-dimethyl-acetamide, pyridine, 1-methyl-2-pyrrolidinone) and [Zn(Indomethacin)2(L1)2] (L1 = ethanol, methanol). Inorg Chem, 2000, 39(17): 3742–3748
Zhou Q D, Hambley T W, Kennedy B J, Lay P A. XAFS studies of anti-inflammatory dinuclear and mononuclear Zn(II) complexes of indomethacin. Inorg Chem, 2003, 42(25): 8557–8566
Jain S, Jain N K, Pitre K S. Electrochemical analysis and analgesic behavior of Zn(II)-baclofen complex. J Pharm Biomed Anal, 2003, 31(5): 1035–1039
Shaheen F, Badshah A, Gielen M, Gieck C, Jamil M, Vos D D. Synthesis, characterization, in vitro cytotoxicity and anti-inflammatory activity of palladium(II) complexes with tertiary phosphines and heterocyclic thiolates: Crystal structure of [PdC28H19N8PS2]. J Inorg Biochem, 2008, 693(6): 1117–1126
Kovala-Demertzi D. Recent advances on non-steroidal anti-inflammatory drugs, NSAIDs: Organotin complexes of NSAIDs. J Organomet Chem, 2006, 691(8): 1767–1774
Ribeiro G, Benadiba M, Colquhoun A, Silva D D O. Diruthenium(II,III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: Synthesis, characterization and their effects on tumor-cell proliferation. Polyhedron, 2008, 27(3): 1131–1137
Ashfaq M, Khan M I, Baloch M K, Malik A. Biologically potent organotin(IV) complexes of 2-maleimidoacetic acid. J Organomet Chem, 2004, 689(1): 238–245
Ashfaq M. Synthesis of novel bioactive phthalimido-4-methyl pentanoateorganotin(IV) esters with spectroscopic investigation. J Organomet Chem, 2006, 691(8): 1803–1808
Partyka M, Au B, Evans C. Cyclodextrins as phototoxicity inhibitors in drug formulations: studies on model systems involving naproxen and beta-cyclodextrin. J Photoch Photobio A, 2001, 140(1): 67–74
Yano H, Hirayama F, Kamada M, Arima H, Uekama K. Colon-specific delivery of prednisolone-appended α-cyclodextrin conjugate: Alleviation of systemic side effect after oral administration. J Controlled Release, 2002, 79(1-3): 103–112
Zhang Y, Wang J Z, Wu Y J. Progress of pharmaceutical studies on superoxide dismutase. Acta Pharm Sinica (in Chinese), 2003, 38(1): 71–74
Valdivia A, Pérez Y, Cao R, Baños M, García A, Villalonga R. Bienzymatic supramolecular complex of catalase modified with cyclodextrin-branched carboxymethylcellulose and superoxide dismutase: Stability and anti-inflammatory properties. Macromol Biosci, 2007, 7(1): 70–75
Wen X H, Liu Z Y, Zhu T Q, Zhu M Q, Jiang K Z, Huang Q Q. Evidence for the 2:1 molecular recognition and inclusion behaviour between β-and γ-cyclodextrins and cinchonine. Bioorg Chem, 2004, 32(4): 223–233
Wong J W, Yuen K H. Improved oral bioavailability of artemisinin through inclusion complexation with β-and γ-cyclodextrins. Int J Pharm, 2001, 227(1-2): 177–185
Dive D, Biot C. Ferrocene conjugates of chloroquine and other antimalarials: The development of ferroquine, a new antimalarial. Chem Med Chem, 2008, 3(3): 383–391
Chibale K, Moss J R, Blackie M, Schalkwyk D V, Smith P J. New amine and urea analogs of ferrochloroquine: synthesis, antimalarial activity in vitro and electrochemical studies. Tetrahedron Lett, 2000, 41(32): 6231–6235
Biot C, Dessolin J, Ricard I, Dive D. Easily synthesized antimalarial ferrocene triazacyclononane quinoline conjugates. J Organomet Chem, 2004, 689(25): 4678–4682
Biot C, Delhaes L, Maciejewski L A, Mortuaire M, Camus D, Dive D, Brocard J S. Synthetic ferrocenic mefloquine and quinine analogues as potential antimalarial agents. Eur J Med Chem, 2000, 35(7-8): 707–714
Biot C, Pradines B, Sergeant M H, Gut J, Rosenthal P J, Chibale K. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. Bioorg Med Chem Lett, 2007, 17(23): 6434–6438
Guillo J, Moreau S, Mouray E, Sinou V, Forfar I, Fabre S B, Desplat V, Millet P, Parzy D, Jarry C, Grellier P. New ferrocenic pyrrolo[1,2-a] quinoxaline derivatives: Synthesis, and in vitro antimalarial activity. Bioorg Med Chem, 2008, 16(20): 9133–9144
Gokhale N H, Padhye S B, Billington D C, Rathbone D L, Croft S L, Kendrick H D, Anson C E, Powell A K. Synthesis and characterization of copper(II) complexes of pyridine-2-carboxami-drazones as potent antimalarial agents. Inorg Chim Acta, 2003, 349: 23–29
Gokhale N H, Padhye S B, Croft S L, Kendrick H D, Davies W, Anson C E, Powell A K. Transition metal complexes of buparvaquone as potent new antimalarial agents 1. Synthesis, X-ray crystal-structures, electrochemistry and antimalarial activity against plasmodium falciparum. J Inorg Biochem, 2003, 95(4): 249–258
Gokhale N H, Shirisha K, Padhye S B, Croft S L, Kendrick H D, Mckee V. Metalloantimalarials: Synthesis, X-ray crystal structure of potent antimalarial copper(II) complex of arylazo-4-hydroxy-1, 2-naphthoquinone. Bioorg Med Chem Lett, 2006, 16(2): 430–432
Dadachova E. Preparation of 198Au(I)-labelled gold-chloroquine complex [198Au(PPh3)(CQ)]PF6 as a petential antimalarial agent. J Labelled Cpd Radiopharm, 1999, 42(3): 287–292
Navarro M, Pekerar S, Pérez H A. Synthesis, characterization and antimalarial activity of new iridium-chloroquine complexes. Polyhedron, 2007, 26(12): 2420–2424
Yuan Y, Zhou C H, Liu Q, Song C Z. New synthetic antibacterial agents. Chin J New Drugs (in Chinese), 2007, 16(5): 343–350
Zhang Y. Progress in research of quinolone antibacteials. Chin J New Drugs, 2006, 15(16): 1344–1356
Mitscher L A. Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial. Chem Rev, 2005, 105(2): 559–592
Psomas G, Tarushi A, Efthimiadou E K, Sanakis Y, Raptopoulou C P, Katsaros N. Synthesis, structure and biological activity of copper(II) complexes with oxolinic acid. J Inorg Biochem, 2006, 100(11): 1764–1773
Tarushi A, Efthimiadou E K, Christofis P, Psomas G. Neutral mononuclear dioxomolybdenum(VI) and dioxouranium(VI) complexes of oxolinic acid: Characterization and biological evaluation. Inorg Chim Acta, 2007, 360(14): 3978–3986
Efthimiadou E K, Sanakis Y, Katsaros N, Karaliota A, Psomas G. Transition metal complexes with the quinolone antibacterial agent pipemidic acid: Synthesis, characterization and biological activity. Polyhedron, 2007, 26(5): 1148–1158
Li Y X, Chen Z F, Xiong R G, Xue Z, Ju H X, You X Z. A mononuclear complex of norfloxacin with silver(I) and its properties. Inorg Chem Commun, 2003, 6(7): 819–822
Refat M S. Synthesis and characterization of norfloxacin-transition metal complexes (group 11, IB): spectroscopic, thermal, kinetic measurements and biological activity. Spectrochim Acta Part A, 2007, 68(5): 1393–1405
Efthimiadou E K, Psomas G, Sanakis Y, Katsaros N, Karaliota A. Metal complexes with the quinolone antibacterial agent N-propylnorfloxacin: Synthesis, structure and bioactivity. J Inorg Biochem, 2007, 101(3): 525–535
Efthimiadou E K, Thomadaki H, Sanakis Y, Raptopoulou C P, Katsaros N, Scorilas A, Karaliota A, Psomas G. Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,20-bipyridine. J Inorg Biochem, 2007, 101(1): 64–73
Efthimiadou E K, Katsaros N, Karaliota A, Psomas G. Mononuclear copper(II) complexes with quinolones and nitrogen-donor heterocyclic ligands: synthesis, characterization, biological activity and interaction with DNA. Inorg Chim Acta, 2007, 360(15): 4093–4102
Turel I, Golic L, Bukovec P, Gubina M. Antibacterial tests of Bismuth(III)-quinolone (ciprofloxacin, cf) compounds against helicobacter pylori and some other bacteria. Crystal structure of (cfH2)2[Bi2Cl10]·4H2O. J Inorg Biochem, 1998, 71(1): 53–60
López-Gresa M P, Ortiz R, Perelló L, Latorre J, Liu-González M, García-granda S, Pérez-Priede M, Cantón E. Interactions of metal ions with two quinolone antimicrobial agents (cinoxacin and ciprofloxacin) spectroscopic and X-ray structural characterization. Antibacterial studies. J Inorg Biochem, 2002, 92(1): 65–74
Efthimiadou E K, Sanakis Y, Katsarou M, Raptopoulou C P, Karaliota A, Katsaros N, Psomas G. Neutral and cationic mononuclear copper(II) complexes with enrofloxacin: structure and biological activity. J Inorg Biochem, 2006, 100(8): 1378–1388
Efthimiadou E K, Katsarou M E, Karaliota A, Psomas G. Copper(II) complexes with sparfloxacin and nitrogen-donor heterocyclic ligands: Structure-activity relationship. J Inorg Biochem, 2008, 102(4): 910–920
Mondelli M, Bruné V, Borthagaray G, Ellena J, Nascimento O R, Leite C Q, Batista A A, Torre M H. New Ni(II)-sulfonamide complexes: synthesis, structural characterization and antibacterial properties. X-ray diffraction of [Ni(sulfisoxazole)2(H2O)4]·2H2O and [Ni(sulfapyridine)2]. J Inorg Biochem, 2008, 102(2): 285–292
Marques L L, Oliveira G M, Lang E S, Campos M M A, Gris L R S. New gold(I) and silver(I) complexes of sulfamethoxazole: synthesis, X-ray structural characterization and microbiological activities of triphenylphosphine(sulfamethoxazolato-N2)gold(I) and (sulfamethoxazolato) silver(I). Inorg Chem Commun, 2007, 10(9): 1083–1087
Chohan Z H, Shaikh A U, Naseer M M. Metal-based isatin-bearing sulfonamides: Their synthesis, characterization and biological properties. Appl Organometal Chem, 2006, 20(11): 729–739
Sharaby C M. Synthesis, spectroscopic, thermal and antimicrobial studies of some novel metal complexes of Schiff base derived from [N1-(4-methoxy-1,2,5-thiadiazol-3-yl)sulfanilamide] and 2-thiophene carboxaldehyde. Spectrochim Acta Part A, 2007, 66(4-5): 1271–1278
Huang J, Cui Z N, Li Y, Yang X L. Bioactivities of copper complexes with schiff bases. Chin J Org Chem (in Chinese), 2008, 28(4): 598–604
Kumar K N, Ramesh R. Synthesis, characterization, redox property and biological activity of Ru(II) carbonyl complexes containing O,N-donor ligands and heterocyclic bases. Spectrochim Acta Part A, 2004, 60(12): 2913–2918
Venkatachalam G, Ramesh R. Catalytic and biological activities of Ru(III) mixed ligand complexes containing N, O donor of 2-hydroxy-1-naphthylideneimines. Spectrochim Acta Part A, 2005, 61(9): 2081–2087
Daniel V P, Murukan B, Kumari B S, Mohanan K. Synthesis, spectroscopic characterization, electrochemical behaviour, reactivity and antibacterial activity of some transition metal complexes with 2-(N-salicylideneamino)-3-carboxyethyl-4,5-dimethylthiophene. Spectrochim Acta Part A, 2008, 70(2): 403–410
Abd-Elzaher M M. Synthesis, characterization, and antimicrobial activity of cobalt(II), nickel(II), copper(II) and zinc(II) complexes with ferrocenyl Schiff bases containing a phenol moiety. Appl Organometa Chem, 2004, 18(4): 149–155
Singh B K, Jetley U K, Sharma R K, Garg B S. Synthesis, characterization and biological activity of complexes of 2-hydroxy-3, 5-dimethylaceto-phenoneoxime(HDMAOX) with copper(II), cobalt (II), nickel(II) and palladium(II). Spectrochimica Acta Part A, 2007, 68(1): 63–73
Prabhakaran R, Geetha A, Thilagavathi M, Karvembu R, Krishnan V, Bertagnolli H, Natarajan K. Synthesis, characterization, EXAFS investigation and antibacterial activities of new ruthenium(III) complexes containing tetradentate Schiff base. J Inorg Biochem, 2004, 98(12): 2131–2140
Bagihalli G B, Avaji P G, Patil S A, Badami P S. Synthesis, spectral characterization, in vitro antibacterial, antifungal and cytotoxic activities of Co(II), Ni(II) and Cu(II) complexes with 1,2,4-triazole Schiff bases. Eur J Med Chem, 2008, 43(12): 2639–2649
Singh K, Barwa M S, Tyagi P. Synthesis, characterization and biological studies of Co(II), Ni(II), Cu(II) and Zn(II) complexes with bidentate Schiff bases derived by heterocyclic ketone. Eur J Med Chem, 2006, 41(1): 147–153
Singh K, Barwa M S, Tyagi P. Synthesis and characterization of cobalt(II), nickel(II), copper(II) and zinc(II) complexes with Schiff base derived from 4-amino-3-mercapto-6-methyl-5-oxo-1,2,4-triazine. Eur J Med Chem, 2007, 42(3): 394–402
Kurtaran R, Yildirim L T, Azaz A D, Namli H, Atakol O. Synthesis, characterization, crystal structure and biological activity of a novel heterotetranuclear complex: [NiLPb(SCN)2(DMF)(H2O)]2, bis-{[μ-N, N′-bis(salicylidene)-1,3-propanediaminato-aqua-nickel(II)](thiocyan ato) (l-thiocyanato) (l-N,N-dimethylformamide)lead(II)}. J Inorg Biochem, 2005, 99(10): 1937–1944
Yildirim L T, Kurtaran R, Namli H, Azaz A D, Atakol O. Synthesis, crystal structure and biological activity of two new heterotrinuclear thiocyanato bridged Cu(II)-Hg(II)-Cu(II) complexes. Polyhedron, 2007, 26(15): 4187–4194
Lv J, Liu T T, Cai S L, Wang X, Liu L, Wang Y M. Synthesis, structure and biological activity of cobalt(II) and copper(II) complexes of valine-derived schiff bases. J Inorg Biochem, 2006, 100(11): 1888–1896
Chohan Z H, Supuran C T. Organometallic compounds with biologically active molecules: in vitro antibacterial and antifungal activity of some 1,1′-(dicarbohydrazono) ferrocenes and their cobalt(II), copper(II), nickel(II) and zinc(II) complexes. Appl Organometal Chem, 2005, 19(12): 1207–1214
Chohan Z H, Khan K M, Supuran C T. Synthesis of antibacterial and antifungal cobalt(II), copper(II), nickel(II) and zinc(II) complexes with bis-(1,1’-disubstituted ferrocenyl)thiocarbohydrazone and bis-(1,1′-disubstituted ferrocenyl)carbohydrazone. Appl Organometal Chem, 2004, 18(7): 305–310
Chitrapriya N, Mahalingam V, Channels L C, Zeller M, Fronczek F R, Natarajan K. Novel Ru(II) oximato complexes with silent oxygen atom: synthesis, chemistry and biological activities. Inorg Chim Acta, 2008, 361(9–10): 2841–2850
El-Behery M, El-Twigry H. Synthesis, magnetic, spectral, and antimicrobial studies of Cu(II), Ni(II) Co(II), Fe(III), and UO2(II) complexes of a new Schiff base hydrazone derived from 7-chloro-4-hydrazinoquinoline. Spectrochimica Acta Part A, 2007, 66(1): 28–36
Özmen Ö ü, Olgun G. Synthesis, characterization and antibacterial activityof new sulfonyl hydrazone derivatives and their nickel(II) complexes. Spectrochim Acta Part A, 2008, 70(3): 641–645
Rodríguez-Argüelles M C, Mosquera-Vázquez S, Tourón-Touceda P, Sanmartiín-Matalobos J, Garca-Deibe A M, Belicchi-Ferrari M, Pelosi G, Pelizzi C, Zani F. Complexes of 2-thiophenecarbonyl and isonicotinoyl hydrazones of 3-(N-methyl)isatin. A study of their antimicrobial activity. J Inorg Biochem, 2007, 101(1): 138–147
Mendes I C, Moreira J P, Mangrich A S, Balena S P, Rodrigues B L, Beraldo H. Coordination to copper(II) strongly enhances the in vitro antimicrobial activity of pyridine-derived N(4)-tolyl thiosemicarbazones. Polyhedron, 2007, 26(13): 3263–3270
Nomiya K, Sekino K, Ishikawa M, Honda A, Yokoyama M, Kasuga N C, Yokoyama H, Nakano S, Onodera K. Syntheses, crystal structures and antimicrobial activities of monomeric 8-coordinate, and dimeric and monomeric 7-coordinate bismuth(III) complexes with tridentate and pentadentate thiosemicarbazones and pentadentate semicarbazone ligands. J Inorg Biochem, 2004, 98(4): 601–615
Kannan S, Sivagamasundari M, Ramesh R, Liu Y. Ruthenium(II) carbonyl complexes of dehydroacetic acid thiosemicarbazone: synthesis, structure, light emission and biological activity. J Organomet Chem, 2008, 693(13): 2251–2257
John R P, Sreekanth A, Rajakannan V, Ajith T A, Kurup M R P. New copper(II) complexes of 2-hydroxyacetophenone N(4)-substituted thiosemicarbazones and polypyridyl co-ligands: Structural, electrochemical and antimicrobial studies. Polyhedron, 2004, 23(16): 2549–2559
Khan S A, Yusuf M. Synthesis, spectral studies and in vitro antibacterial activity of steroidal thiosemicarbazone and their palladium (Pd(II)) complexes. Eur J Med Chem, 2009, doi:10.1016/j.ejmech
Rodríguez-Argüelles M C, López-Silva E C, Sanmartín J, Pelagatti P, Zani F. Copper complexes of imidazole-2-, pyrrole-2- and indol-3-carbaldehyde thiosemicarbazones: Inhibitory activity against fungi and bacteria. J Inorg Biochem, 2005, 99(11): 2231–2239
Bacchi A, Carcelli M, Pelagatti P, Pelizzi G, Rodriguez-Arguelles M C, Rogolino D, Solinas C, Zani d F. Antimicrobial and mutagenic properties of organotin(IV) complexes with isatin and N-alkylisatin bisthiocarbonohydrazones. J Inorg Biochem, 2005, 99(2): 397–408
Li Q X, Tang H A, Li Y Z, Wang M, Wang L F, Xia C G. Synthesis, characterization, and antibacterial activity of novel Mn(II), Co(II), Ni(II), Cu(II), and Zn(II) complexes with vitamin K3-thiosemicarbazone. J Inorg Biochem, 2000, 78(2): 167–174
Zhang Y, Xiao X, Deng P X, Huang Q M, Pan Z Q, Chen Z P. Synthesis and antibacterial activity of β-substituted metalporphyrins of 1-naphthol. J Wuhan Inst Tech (in Chinese), 2008, 30(4): 8–11
Sreedaran S, Bharathi K S, Rahiman A K, Rajesh K, Nirmala G, Jagadish L, Kaviyarasan V, Narayanan V. Synthesis, electrochemical, catalytic and antimicrobial activities of novel unsymmetrical macrocyclic dicompartmental binuclear nickel(II) complexes. Polyhedron, 2008, 27(7): 1867–1874
Singh D P, Kumar R, Singh J. Synthesis and spectroscopic studies of biologically active compounds derived from oxalyldihydrazide and benzil, and their Cr(III), Fe(III) and Mn(III) complexes. Eur J Med Chem, 2009, doi:10.1016/j.ejmech.2008.03.007 (in press)
Reddy P M, Prasad A V S S, Shanker K, Ravinder V. Synthesis, spectral studies and antibacterial activity of novel macrocyclic Co(II) compounds. Spectrochim Acta Part A, 2007, 68(3): 1000–1006
Chandra S, Sangeetika. Spectroscopic, redox and biological activities of transition metal complexes with one donor macrocyclic ligand derived from semicarbazide and thiodiglycolic acid. Spectrochim Acta Part A, 2004, 60(8): 2153–2162
Shakir M, Azim Y, Chishti H T N, Parveen S. Synthesis, characterization of complexes of Co(II), Ni(II), Cu(II) and Zn(II) with 12-membered Schiff base tetraazamacrocyclic ligand and the study of their antimicrobial and reducing power. Spectrochim Acta Part A, 2006, 65(2): 490–496
Singh A P, Kaushik N K, Verma A K, Hundal G, Gupta R. Synthesis, structure and biological activity of copper(II) complexes of 4-(2-pyridylmethyl)-1,7-dimethyl-1,4,7-triazonane-2,6-dione and 4-(2-pyridylethyl)-1,7-dimethyl-1,4,7-triazonane-2,6-dione. Eur J Med Chem, 2009, doi:10.1016/j.ejmech.2008.07.029 (in press)
Roy T G, Hazari S K S, Dey B K, Miah H A, Olbrich F, Rehder D. Synthesis and antimicrobial activities of isomers of N(4), N(II)-dimethyl-3,5,7,7,10,12,14,14-octamethyl-1,4,8,11-tetraazacycl o tetradecane and their nickel(II) complexes. Inorg Chem, 2007, 46(13): 5372–5380
Khanmohammadi H, Arabahmadi R, Abnosi M H, Khavasi H R. Synthesis, crystal structure, spectral and biological studies of CuII-MII(M = Zn and Pb)heterodinuclear complexes of new phenol-based macrocyclic ligands. Polyhedron, 2007, 26(17): 4963–4970
Guerra W, Azevedo E A, Monteiro A R S, Bucciarelli-Rodriguez M, Chartone-Souza E, Nascimento A M A, Fontes A P S, Moyec L L, Pereira-Maia E C, Chartone-Souza E. Synthesis, characterization, and antibacterial activity of three palladium(II) complexes of tetracyclines. J Inorg Biochem, 2005, 99(12): 2348–2354
Refat M S. Complexes of uranyl(II), vanadyl(II) and zirconyl(II) with orotic acid “vitamin B13”: Synthesis, spectroscopic, thermal studies and antibacterial activity. J Mol Struct, 2007, 842(1-3): 24–37
Kumar R S, Arunachalam S. DNA binding and antimicrobial studies of some polyethyleneimine-copper(II) complex samples containing 1,10-phenanthroline and L-theronine as co-ligands. Polyhedron, 2007, 26(13): 3255–3262
Muthukumar M, Viswanathamurthi P, Natarajan K. Synthesis and spectral characterization of 2′-hydroxy chalconate complexes of ruthenium(II) and their catalytic and biological applications. Spectrochimica Acta Part A, 2008, 70(5): 1222–1226
Rodríguez-Fernández E, Manzano J L, Benito J J, Hermosa R, Monte E, Criado J J. Thiourea, triazole and thiadiazine compounds and their metal complexes as antifungal agents. J Inorg Biochem, 2005, 99(8): 1558–1572
Mi J L, Zhou C H, Bai X. Advances in triazole antimicrobial agents. Chin J Antibiotics (in Chinese), 2007, 32(10): 587–593
Rowan R, Tallon T, Sheahan A M, Curran R, McCann M, Kavanagh K, Devereux M, McKee V. ’silver bullets’ in antimicrobial chemotherapy: Synthesis, characterisation and biological screening of some new Ag(II)-containing imidazole complexes. Polyhedron, 2006, 25(8): 1771–1778
McCann M, Coyle B, Briody J, Bass F, O’Gorman N, Devereux M, Kavanagh K, McKee V. Synthesis and antimicrobial activity of (Z)-3-(1H-imidazol-1-yl)-2-phenylpropenenitrile and its metal complexes: X-ray crystal structures of the Zn(II) and Ag(II) complexes. Polyhedron, 2003, 22(12): 1595–1601
Mashaly M M, El-Shafiy H F, El-Maraghy S B, Habib H A. Synthesis, properties and thermal studies of oxorhenium(II) complexes with 3-hydrazino-5,6-diphenyl-1,2,4-triazine, benzimidazolethione and 2-hydrazinobenzimidazole mixed ligand complexes, pyrolytical products and biological activity. Spectrochim Acta Part A, 2005, 61(8): 1853–1869
Mastrolorenzo A, Scozzafava A, Supuran C T. Antifungal activity of silver and zinc complexes of sulfadrug derivatives incorporating arylsulfonylureido moieties. Eur J Pharmaceu Sci, 2000, 11(2): 99–107
Bellú S, Hure E, Trapé M, Trossero C, Molina G, Drogo C, Williams P A M, Atria A M, Acevedo J C M, Zacchino S, Sortino M, Campagnoli D, Rizzotto M. Synthesis, structure and antifungal properties of Co(II)-sulfathiazolate complexes. Polyhedron, 2005, 24(4): 501–509
Creaven B S, Egan D A, Karcz D, Kavanagh K, McCann M, Mahon M, Noble A, Thati B, Walsh M. Synthesis, characterisation and antimicrobial activity of copper(II) and manganese(II) complexes of coumarin-6,7-dioxyacetic acid (cdoaH2) and 4-methylcoumarin-6,7-dioxyacetic acid (4-MecdoaH2): X-ray crystal structures of [Cu(cdoa)-(phen)2]·8.8H2O and [Cu(4-Mecdoa)(phen)2]·13H2O (phen=1,10-phenanthroline). J Inorg Biochem, 2007, 101(8): 1108–1119
How F N F, Crouse K A, Tahir M I M, Tarafder M T H, Cowley A R. Synthesis, characterization and biological studies of S-benzyl-β-N-(benzoyl) dithiocarbazate and its metal complexes. Polyhedron, 2008, 27(15): 3325–3329
Devereux M, McCann M, Shea D O, Kelly R, Egan D, Deegan C, Kavanagh K, McKee V, Finn G. Synthesis, antimicrobial activity and chemotherapeutic potential of inorganic derivatives of 2-(4′-thiazolyl) benzimidazole{thiabendazole}: X-ray crystal structures of [Cu(TBZH)2Cl]Cl·H2O·EtOH and TBZH2NO3 (TBZH = thiabendazole). J Inorg Biochem, 2004, 98(6): 1023–1031
Hothi H S, Makkar A, Sharma J R, Manrao M R. Synthesis and antifungal potential of Co(II) complexes of 1-(2′-hydroxyphenyl) ethylideneanilines. Eur J Med Chem, 2006, 41(2): 253–255
Singh V P, Katiyar A. Synthesis, spectral characterization and antimicrobial activity of some transition metal(II) complexes with acetone p-amino acetophenone benzoylhydrazone. Pesticide Biochem Physiol, 2008, 92(1): 8–14
Jouada E M, Larcherb G, Allain M, Riou A, Boueta G M, Khan M A, Thanh X D. Synthesis, structure and biological activity of nickel(II) complexes of 5-methyl-2-furfural thiosemicarbazone. J Inorg Biochem, 2001, 86(2): 565–571
Ali M A, Mirza A H, Hossain A M S, Nazimuddin M. Synthesis, characterization, antifungal properties and X-ray crystal structures of five- and six-coordinate copper(II) complexes of the 6-methyl-2-formylpyridine 4 N-dimethylthiosemicarbazone. Polyhedron, 2001, 20(9–10): 1045–1052
Loginova N V, Koval’chuk T V, Zheldakova R A, Chernyavskaya A A, Osipovich N P, Glushonok G K, Polozov G I, Povalishev V N, Sorokin V L, Shadyro O I. Synthesis, characterization and antifungal activity of copper (II) complexes of sterically hindered o-diphenol derivatives. Polyhedron, 2006, 25(18): 3603–3610
Loginova N V, Koval’chuk T V, Polozov G I, Osipovich N P, Rytik P G, Kucherov I I, Chernyavskaya A A, Sorokin V L, Shadyro O I. Synthesis, characterization, antifungal and anti-HIV activities of metal(II) complexes of 4,6-di-tert-butyl-3-[(2-hydroxyethyl)thio] benzene-1,2-diol. Eur J Med Chem, 2008, 43(7): 1536–1542
Bottari B, Maccari R, Monforte F, Ottanà R, Rotondo E, Vigorita M G. Isoniazid-related copper(II) and nickel(II) complexes with antimycobacterial in vitro activity. Part 9. Bioorg Med Chem Lett, 2000, 10(7): 657–660
Maccari R, Ottanà R, Bottari B, Rotondo E, Vigorita M G. In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones. Bioorg Med Chem Lett, 2004, 14(23): 5731–5733
Bottari B, Maccari R, Monforte F, Ottanà R, Vigorita M G, Bruno G, Nicolò F, Rotondo A, Rotondo E. Nickel(II) 2,6-diacetylpyridine bis(isonicotinoylhydrazonate) and bis(benzoylhydrazonate) complexes: Structure and antimycobacterial evaluation. Part XI. Bioorg Med Chem, 2001, 9(8): 2203–2211
Sandbhor U, Padhye S, Billington D, Rathbone D, Franzblau S, Anson C E, Powell A K. Metal complexes of carboxamidrazone analogs as antitubercular agents 1. Synthesis, X-ray crystal-structures, spectroscopic properties and antimycobacterial activity against mycobacterium tuberculosis H37Rv. J Inorg Biochem, 2002, 90(3–4): 127–136
Saha D K, Padhye S, Anson C E, Powell A K. Hydrothermal synthesis, crystal structure, spectroscopy, electrochemistry and antimycobacterial evaluation of the copper (II) ciprofloxacin complex: [Cu(cf)2-(BF4)2]·6H2O. Inorg Chem Commun, 2002, 5(12): 1022–1027
Saha D K, Sandbhor U, Shirisha K, Padhye S, Deobagkar D, Anson C E, Powell A K. A novel mixed-ligand antimycobacterial dimeric copper complex of ciprofloxacin and phenanthroline. Bioorg Med Chem Lett, 2004, 14(12): 3027–3032
Razafimahefa D, Ralambomanana D A, Hammouche L, Pélinski L, Lauvagie S, Bebear C, Brocard J, Maugein J. Synthesis and antimycobacterial activity of ferrocenyl ethambutol analogues and ferrocenyl diamines. Bioorg Med Chem Lett, 2005, 15(9): 2301–2303
Cuin A, Massabni A C, Leite C Q F, Sato D N, Neves A, Szpoganicz B, Silva M S, Bortoluzzi A J. Synthesis, X-ray structure and antimycobacterial activity of silver complexes with α-hydroxycarboxylic acids. J Inorg Biochem, 2007, 101(2): 291–296
Cavicchioli M, Leite C Q F, Sato D N, Massabni A C. Synthesis, characterization and antimycobacterial activity of Ag(I)-aspartame, Ag(I)-saccharin and Ag(I)-cyclamate complexes. Arch Pharm Chem Life Sci, 2007, 340(10): 538–542
Ventura C A, Giannone I, Musumeci T, Pignatello R, Ragni L, Landolfi C, Milanese C, Paolino D, Puglisi G. Physico-chemical characterization of disoxaril-dimethyl-β-cyclodextrin inclusion complex and in vitro permeation studies. Eur J Med Chem, 2006, 41(2): 233–240
Liang X Y, Sadler P J. Cyclam complexes and their applications in medicine. Chem Soc Rev, 2004, 33(4): 246–266
Turel I, Bukovec N, Goodgame M, Williams D J. Synthesis and characterization of copper(II) coordination compounds with acyclovir: crystal structure of triaquabis [9-{(2-hydroxyethoxy) methyl}guanine]copper(II)nitrate(V)hydrate. Polyhedron, 1997, 16(10): 1701–1706
Turel I, Andersen B, Sletten E, White A J P, Williams D J. New studies in the copper(II) acyclovir (acv) system. NMR relaxation studies and the X-ray crystal structure of [Cu(acv)2(H2O)2](NO3)2. Polyhedron, 1998, 17(23–24): 4195–4201
García-Raso Á, Fiol J J, Bádenas F, Cons R, Terrón Á, Quirós M. Synthesis and structural characteristics of metal-acyclovir (ACV) complexes: [Ni(or Co)(ACV)2 (H2O)4]Cl2·2ACV, [Zn(ACV)Cl2-(H2O)], [Cd(ACV)Cl2] H2O and [{Hg(ACV)Cl2 2}x]. Recognition of acyclovir by Ni-ACV. J Chem Soc Dalton Trans, 1999, 2: 167–173
Panagiotopoulou A, Katsaros N, Masi N G D, Natile G. Synthesis and characterisation of platinum(II) complexes with the antiviral agents ftorafur and furavir. Inorg Chim Acta, 2001, 325(1–2): 73–78
Wooley P H, Whalen J D, The influence of superoxide scavenging compound CTC 23 on type. collagen-induced arthritis in mice. Agents Actions, 1992, 35(3–4): 273–279
Schwartz J A, Lium E K, Verstein S J S. Herpes simplex virus type I entry is inhibited by the cobalt chelate complex CTC-96. J Virology, 2001, 75(9): 4117–4128
Delehanty J B, Bongard J E, Thach D C, Knight D A, Hickey T E, Chang E L. Antiviral properties of cobalt(III)-complexes. Bioorg Med Chem, 2008, 16(2): 830–837
Allardyce C S, Dyson P J, Ellis D J, Salter P A, Scopelliti R. Synthesis and characterisation of some water soluble ruthenium(II)-arene complexes and an investigation of their antibiotic and antiviral properties. J Organomet Chem, 2003, 668(1-2): 35–42
Koester L S, Bertuol, J B, Groch K R, Xavier C R, Moellerke R, Mayorga P, Costa T D, Bassani V L, Bioavailability of carbamazepine: β-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets. Eur J Pharm Sci, 2004, 22(2-3): 201–207
Beraldo H, Sinisterra R D, Teixeira L R, Vieira R P, Doretto M C. An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-β-cyclodextrin and benzaldehyde semicarbazone. Biochem Biophys Res Commun, 2002, 296(2): 241–246
Viossat B, Daran J C, Savouret G, Morgant G, Greenaway F T, Dung N H, Pham-Tran V A, Sorenson J R J. Low-temperature (180 K) crystal structure, electron paramagnetic resonance spectroscopy, and propitious anticonvulsant activities of Cu2 II(aspirinate)4(DMF)2 and other Cu2 II.(aspirinate)4 chelates. J Inorg Biochem, 2003, 96(2-3): 375–385
Viossat B, Greenaway F T, Morgant G, Daran J C, Dung N H, Sorenson J R J. Low-temperature (180 K) crystal structures of tetrakis-μ-(niflumato)di(aqua)dicopper(II) N,N-dimethylformamide and N,N-dimethylacetamide solvates, their EPR properties, and anticonvulsant activities of these and other ternary binuclear copper (II)niflumate complexes. J Inorg Biochem, 2005, 99(2): 355–367
Lemoine P, Viossat B, Dung N H, Tomas A, Morgant G, Greenaway F T, Sorenson, J R J. Synthesis, crystal structures, and anti-convulsant activities of ternary [ZnII(3,5-dIIsopropylsalicylate)2], [ZnII(salicylate)2] and [ZnII(aspirinate)2] complexes. J Inorg Biochem, 2004, 98(11): 1734–1749
d’Angelo J, Morgant G, Ghermani N E, Desmaële D, Fraisse B, Bonhomme F, Dichi E, Sghaier M, Li Y L, Journaux Y, Sorenson J R J. Crystal structures and physico-chemical properties of Zn(II) and Co(II) tetraaqua(3-nitro-4-hydroxybenzoato) complexes: their anticonvulsant activities as well as related (5-nitrosalicylato)-metal complexes. Polyhedron, 2008, 27(2): 537–546
Wang Z, Hirayama F, Uekama K. In-vivo and in-vitro evaluations of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcelluloses in dogs. J Pharm Pharmacol, 1994, 46(6): 505–507
Ikeda Y, Kimura K, Hirayama F, Arima H, Uekama K. Controlled release of a water-soluble drug, captopril, by a combination of hydrophilic and hydrophobic cyclodextrin derivatives. J Controlled Release, 2000, 66(2–3): 271–280
Kopecky F, Kopecka B, Kaclik P. Dissolution of nimodipine in an aqueous solution of hydroxyethyl-beta-cyclodextrin and a review of solubility of nimodipine with cyclodextrins. Ceska Slov Farm, 2003, 52(1): 33–38
Fernandes C M, Veiga F J B. Effect of the hydrophobic nature of triacetyl-β-cyclodextrin on the complexation with nicardipine hydrochloride: physicochemical and dissolution properties of the kneaded and spray-dried complexes. Chem Pharm Bull, 2002, 50(12): 1597–1602
Nagase Y, Hirata M, Wada K, Arima H, Hirayama F, Irie T, Kikuchi M, Uekama K. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether β-cyclodextrin. Int J Pharm, 2001, 229(1–2): 163–172
Nagase Y, Arima H, Wada K, Sugawara T, Satoh H, Hirayama F, Uekama K. Inhibitory effect of sulfobutyl ether β-cyclodextrin on DY-9760e-induced cellular damage: In vitro and in vivo studies. J Pharm Sci, 2003, 92(12): 2466–2474
Judenhofer M S, Wehrl H F, Newport D F, Catana C, Siegel S B, Becker M, Thielscher A, Kneilling M, Lichy M P, Eichner M, Klingel K, Reischl G, Widmaier S, Röcken M, Nutt R E, Machulla H J, Uludag K, Cherry S R, Claussen C D, Pichler B J. Simultaneous PET-MRI: A new approach for functional and morphological imaging. Nat Med, 2008, 14(4): 459–465
Caravan P, Ellison J J, McMurry T J, Lauffer R B. Gadolinium (II) chelates as MRI contrast agents: Structure, dynamics, and applications. Chem Rev, 1999, 99(9): 2293–2352
Parker D, Dickins R S, Puschmann H, Crossland C, Howard J A K. Being Excited by lanthanide coordination complexes: Aqua species, chirality, excited-state chemistry, and exchange dynamics. Chem Rev, 2002, 102(6): 1977–2010
Bellin M F. MR contrast agents, the old and the new. Eur J Radiol, 2006, 60(3): 314–323
Aime S, Crich S G, Gianolio E, Giovenzana G B, Tei L, Terreno E. High sensitivity lanthanide(III) based probes for MR-medical imaging. Coord Chem Rev, 2006, 250(11–12): 1562–1579
Lattuada L, Demattio S, Vincenzi V, Cabella C, Visigalli M, Aime S, Crich S G, Gianolio E. Magnetic resonance imaging of tumor cells by targeting the amino acid transport system. Bioorg Med Chem Lett, 2006, 16(15): 4111–4114
Hermann P, Kotek J, Kubícek V, Lukš I. Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Dalton Trans, 2008, 23: 3027–3047
Yan G P, Robinson L, Hogg P. Magnetic resonance imaging contrast agents: Overview and perspectives. Radiography, 2007, 13(1): e5–e19
Feng J H, Sun G Y, Pei F K, Liu M L. Comparison between Gd-DTPA and several bisamide derivatives as potential MRI contrast agents. Bioorg Med Chem, 2003, 11(15): 3359–3366
Caravan P, Cloutier N J, Greenfield M T, McDermid S A, Dunham S U, Bulte J W, Amedio M J C, Looby J R J, Supkowski R M, Horrocks W D, McMurry J T J, Lauffer R B. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc, 2002, 124(12): 3152–3162
Chong H S, Garmestani K, Bryant L H, Milenic J D E, Overstreet T, Birch N, Le T, Brady E D, Brechbiel M W, Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging. J Med Chem, 2006, 49(6): 2055–2062
Corot C, Port M, Raynal I, Dencausse A, Schaefer M, Rousseaux O, Simonot C, Devoldere L, Lin J, Foulon M, Bourrinet P, Bonnemain B. Meyer D. Physical, chemical, and biological evaluations of P760: A new gadolinium complex characterized by a low rate of interstitial diffusion. J Magn Reson Imaging, 2000, 11(2): 182–191
Delgado R, Félix V, Lima L M P, Price D W. Metal complexes of cyclen and cyclam derivatives useful for medical applications: A discussion based on thermodynamic stability constants and structural data. Dalton Trans, 2007, 26: 2734–2745
Hovland R, Gløgård C, Aasen A J, Klaveness J. Gadolinium DO3A derivatives mimicking phospholipids: preparation and in vitro evaluation as pH responsive MRI contrast agents. J Chem Soc, Perkin Trans, 2001, 2(6): 929–933
Xiang Q X, Xia C Q, Yu X Q, Zhang L Q, Xie R G. Recent advances in macrocyclic polyamines and their metal complexes. Chin J Org Chem (in Chinese), 2004, 24(9): 981–986
Chong H S, Song H A, Ma X, Milenic D E, Brady E D, Lim S Y, Lee H S, Baidoo K E, Cheng D F, Brechbiel M W. Novel bimodal bifunctional ligands for adioimmunotherapy and targeted MRI. Bioconjugate Chem. 2008, 19(7): 1439–1447
Cavagna F M, Lorusso V, Anelli P L, Maggioni F, de-Haën C. Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), A new intravascular contrast medium for MRI. Acad Radiol. 2002, 9(2): 491–494
Rudovský J, Botta M, Hermann P, Hardcastle K I, Lukey I, Aime S. PAMAM dendrimeric conjugates with a Gd-DOTA phosphinate derivative and their adducts with polyaminoacids: The interplay of global motion, internal rotation, and fast water exchange. Bioconjugate Chem, 2006, 17(4): 975–987
Battistini E, Gianolio E, Gref R, Couvreur P, Fuzerova S, Othman M, Aime S, Badet B, Durand P. High-relaxivity magnetic resonance imaging (MRI) contrast agent based on supramolecular assembly between a gadolinium chelate, a modified dextran, and poly-β-cyclodextrin. Chem Eur J, 2008, 14(15): 4551–4561
Khafagy E S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: Acomparative review. Adv Drug Deliv Rev, 2007, 59(15): 1521–1546
Sajeesh S, Sharma C P. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm, 2006, 325(1–2): 147–154
Higashi T, Hirayama F, Misumi S, Arima H, Uekama K. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system. Biomaterials, 2008, 29(28): 3866–3871
Suihko E, Korhonen O, Järvinen T, Ketolainen J, Jarho P, Laine E, Paronen P. Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-β-cyclodextrin. Int J Pharm, 2001, 215(1–2): 137–145
Guiotoku M, Silva F R M B, Azzolini J C, Mercê A L R, Mangrich A S, Sala L F, Szpoganicz B. Monosaccharides and the VO(IV) metal ion: equilibrium, thermal studies and hypoglycemic effect. Polyhedron, 2007, 26(6): 1269–1276
Hidetoshi A, Kiyokazu Y, Kouzou M, Tetsumi I, Fumitoshi H, Kaneto U. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci, 2001, 90(6): 690–701
Bom A, Bradley M, Cameron K, Clark J K., Van E J, Feilden H, Maclean E J, Muir A W, Palin R, Rees D C, Zhang M Q. A novel concept of reversing neuromuscular block: Chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl, 2002, 41(2): 266–270
Virués C, Zquez E F V, Inoue M B, Inoue M. NMR studies of host guest complexes of anionic cyclophanes with dopamine and its analogues in aqueous media. J Inclusion Phenom Macrocyclic Chem, 2004, 48(3–4): 141–146
Yoon J, Kim S K, Singh N J, Kim K S. Imidazolium receptors for the recognition of anions. Chem Soc Rev, 2006, 35(4): 355–360
Baker M V, Brown D H, Heath C H, Skelton B W, White A H, Williams C C. Azolium-linked cyclophanes: Effects of structure, solvent, and counteranions on solution conformation behavior. J Org Chem, 2008, 73(23): 9340–9352
Baker M V, Bosnich M J, Brown D H, Byrne L T, Hesler V J, Skelton B W, White A H, Williams C C. Azolium-linked cyclophanes: A comprehensive examination of conformations by 1H NMR spectroscopy and structural studies. J Org Chem, 2004, 69(22): 7640–7652
Zhou C H. Design and synthesis of imidazolium cyclophanes and their biomimetic chemistry. Dissertation for the Doctoral Degree (in Chinese). Chengdu: Sichuan University, 1996
Zuo Z, Tam Y K, Diakur J, Wiebe L I. Hydroxypropyl-beta- cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. J Pharm Pharm Sci, 2002, 5(3): 292–298
Bary A R, Tucker I G, Davies N M. Considerations in the use of hydroxypropyl-beta-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone. Eur J Pharm Biopharm, 2000, 50(2):: 237–244
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the Southwest University (Grant Nos. SWUB2006018 & XSGX0602), the Natural Science Foundation of Chongqing (Grant Nos. 2007BB5369 & 2006BB4341) and the Key Project from the Personnel Department of China (Grant No. 2002-99)
Rights and permissions
About this article
Cite this article
Zhou, C., Gan, L., Zhang, Y. et al. Review on supermolecules as chemical drugs. Sci. China Ser. B-Chem. 52, 415–458 (2009). https://doi.org/10.1007/s11426-009-0103-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11426-009-0103-2